319 related articles for article (PubMed ID: 26320171)
1. Calmodulin antagonists promote TRA-8 therapy of resistant pancreatic cancer.
Yuan K; Yong S; Xu F; Zhou T; McDonald JM; Chen Y
Oncotarget; 2015 Sep; 6(28):25308-19. PubMed ID: 26320171
[TBL] [Abstract][Full Text] [Related]
2. Calmodulin Binding to Death Receptor 5-mediated Death-Inducing Signaling Complex in Breast Cancer Cells.
Fancy RM; Kim H; Zhou T; Zinn KR; Buchsbaum DJ; Song Y
J Cell Biochem; 2017 Aug; 118(8):2285-2294. PubMed ID: 28092099
[TBL] [Abstract][Full Text] [Related]
3. Calmodulin antagonist enhances DR5-mediated apoptotic signaling in TRA-8 resistant triple negative breast cancer cells.
Fancy RM; Kim H; Napier T; Buchsbaum DJ; Zinn KR; Song Y
J Cell Biochem; 2018 Jul; 119(7):6216-6230. PubMed ID: 29663486
[TBL] [Abstract][Full Text] [Related]
4. PARP-1 regulates resistance of pancreatic cancer to TRAIL therapy.
Yuan K; Sun Y; Zhou T; McDonald J; Chen Y
Clin Cancer Res; 2013 Sep; 19(17):4750-9. PubMed ID: 23833311
[TBL] [Abstract][Full Text] [Related]
5. Calmodulin binding to the Fas-mediated death-inducing signaling complex in cholangiocarcinoma cells.
Chen Y; Pawar P; Pan G; Ma L; Liu H; McDonald JM
J Cell Biochem; 2008 Feb; 103(3):788-99. PubMed ID: 17654480
[TBL] [Abstract][Full Text] [Related]
6. Cytoplasmic PARP-1 promotes pancreatic cancer tumorigenesis and resistance.
Xu F; Sun Y; Yang SZ; Zhou T; Jhala N; McDonald J; Chen Y
Int J Cancer; 2019 Jul; 145(2):474-483. PubMed ID: 30614530
[TBL] [Abstract][Full Text] [Related]
7. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
Hari Y; Harashima N; Tajima Y; Harada M
Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
[TBL] [Abstract][Full Text] [Related]
8. Synergistic induction of apoptosis in breast cancer cells by tamoxifen and calmodulin inhibitors.
Frankfurt OS; Sugarbaker EV; Robb JA; Villa L
Cancer Lett; 1995 Nov; 97(2):149-54. PubMed ID: 7497456
[TBL] [Abstract][Full Text] [Related]
9. Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5.
Adams C; Totpal K; Lawrence D; Marsters S; Pitti R; Yee S; Ross S; Deforge L; Koeppen H; Sagolla M; Compaan D; Lowman H; Hymowitz S; Ashkenazi A
Cell Death Differ; 2008 Apr; 15(4):751-61. PubMed ID: 18219321
[TBL] [Abstract][Full Text] [Related]
10. Understanding of tolerance in TRAIL-induced apoptosis and cancelation of its machinery by α-mangostin, a xanthone derivative.
Kumazaki M; Shinohara H; Taniguchi K; Ueda H; Nishi M; Ryo A; Akao Y
Oncotarget; 2015 Sep; 6(28):25828-42. PubMed ID: 26304927
[TBL] [Abstract][Full Text] [Related]
11. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs.
Ganten TM; Haas TL; Sykora J; Stahl H; Sprick MR; Fas SC; Krueger A; Weigand MA; Grosse-Wilde A; Stremmel W; Krammer PH; Walczak H
Cell Death Differ; 2004 Jul; 11 Suppl 1():S86-96. PubMed ID: 15105837
[TBL] [Abstract][Full Text] [Related]
12. A novel TRAIL mutant-TRAIL-Mu3 enhances the antitumor effects by the increased affinity and the up-expression of DR5 in pancreatic cancer.
Huang M; Zhu H; Yi C; Yan J; Wei L; Yang X; Chen S; Huang Y
Cancer Chemother Pharmacol; 2018 Nov; 82(5):829-838. PubMed ID: 30167846
[TBL] [Abstract][Full Text] [Related]
13. Capsaicin sensitizes TRAIL-induced apoptosis through Sp1-mediated DR5 up-regulation: involvement of Ca(2+) influx.
Moon DO; Kang CH; Kang SH; Choi YH; Hyun JW; Chang WY; Kang HK; Koh YS; Maeng YH; Kim YR; Kim GY
Toxicol Appl Pharmacol; 2012 Feb; 259(1):87-95. PubMed ID: 22200406
[TBL] [Abstract][Full Text] [Related]
14. Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model.
Buchsbaum DJ; Zhou T; Grizzle WE; Oliver PG; Hammond CJ; Zhang S; Carpenter M; LoBuglio AF
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3731-41. PubMed ID: 14506165
[TBL] [Abstract][Full Text] [Related]
15. Calmodulin antagonists induce platelet apoptosis.
Wang Z; Li S; Shi Q; Yan R; Liu G; Dai K
Thromb Res; 2010 Apr; 125(4):340-50. PubMed ID: 20172594
[TBL] [Abstract][Full Text] [Related]
16. Enhanced apoptosis following treatment with TRA-8 anti-human DR5 monoclonal antibody and overexpression of exogenous Bax in human glioma cells.
Kaliberov S; Stackhouse MA; Kaliberova L; Zhou T; Buchsbaum DJ
Gene Ther; 2004 Apr; 11(8):658-67. PubMed ID: 14973547
[TBL] [Abstract][Full Text] [Related]
17. Triptolide sensitizes pancreatic cancer cells to TRAIL-induced activation of the death receptor pathway.
Chen Z; Sangwan V; Banerjee S; Chugh R; Dudeja V; Vickers SM; Saluja AK
Cancer Lett; 2014 Jun; 348(1-2):156-66. PubMed ID: 24662747
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Notch1 signaling overcomes resistance to the death ligand Trail by specificity protein 1-dependent upregulation of death receptor 5.
Fassl A; Tagscherer KE; Richter J; De-Castro Arce J; Savini C; Rösl F; Roth W
Cell Death Dis; 2015 Oct; 6(10):e1921. PubMed ID: 26469969
[TBL] [Abstract][Full Text] [Related]
19. The long non-coding RNA HOTAIR enhances pancreatic cancer resistance to TNF-related apoptosis-inducing ligand.
Yang SZ; Xu F; Zhou T; Zhao X; McDonald JM; Chen Y
J Biol Chem; 2017 Jun; 292(25):10390-10397. PubMed ID: 28476883
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the Interactions between Calmodulin and Death Receptor 5 in Triple-negative and Estrogen Receptor-positive Breast Cancer Cells: AN INTEGRATED EXPERIMENTAL AND COMPUTATIONAL STUDY.
Fancy RM; Wang L; Zeng Q; Wang H; Zhou T; Buchsbaum DJ; Song Y
J Biol Chem; 2016 Jun; 291(24):12862-12870. PubMed ID: 27129269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
